| Mark Wesley Osorio, OD | |
|
29500 7 Mile Rd, Livonia, MI 48152-1910 | |
| (248) 477-2662 | |
| Not Available |
| Full Name | Mark Wesley Osorio |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 41 Years |
| Location | 29500 7 Mile Rd, Livonia, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467666248 | NPI | - | NPPES |
| 9000H11345-0 | Other | MI | BSBC OF MI. |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4901004087 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Svs Vision Inc | 9931257110 | 22 |
News Archive
Research presented today at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo shows that a questionnaire-based algorithm predicts the risk of a pregnant woman developing preeclampsia.
By using a modern genome-wide knockout approach to single out coronavirus host factors in human cells, researchers from Rega Institute in Belgium discovered a potential new target that might be exploited for developing drugs against the ongoing coronavirus disease (COVID-19) pandemic, but also future outbreaks of highly pathogenic coronaviruses
RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.
Scientists say they are a step closer to developing a drug to kill the trypanosome parasite that causes human African trypanosomiasis, otherwise known as sleeping sickness, paving the way for a potential cure.
› Verified 2 days ago
| Provider Name | Svs Vision Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1194879023 PECOS PAC ID: 9931257110 Enrollment ID: O20090427000507 |
News Archive
Research presented today at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo shows that a questionnaire-based algorithm predicts the risk of a pregnant woman developing preeclampsia.
By using a modern genome-wide knockout approach to single out coronavirus host factors in human cells, researchers from Rega Institute in Belgium discovered a potential new target that might be exploited for developing drugs against the ongoing coronavirus disease (COVID-19) pandemic, but also future outbreaks of highly pathogenic coronaviruses
RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.
Scientists say they are a step closer to developing a drug to kill the trypanosome parasite that causes human African trypanosomiasis, otherwise known as sleeping sickness, paving the way for a potential cure.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Wesley Osorio, OD 5893 Tower Rd, Plymouth, MI 48170-5032 Ph: (734) 459-1297 | Mark Wesley Osorio, OD 29500 7 Mile Rd, Livonia, MI 48152-1910 Ph: (248) 477-2662 |
News Archive
Research presented today at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo shows that a questionnaire-based algorithm predicts the risk of a pregnant woman developing preeclampsia.
By using a modern genome-wide knockout approach to single out coronavirus host factors in human cells, researchers from Rega Institute in Belgium discovered a potential new target that might be exploited for developing drugs against the ongoing coronavirus disease (COVID-19) pandemic, but also future outbreaks of highly pathogenic coronaviruses
RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.
Scientists say they are a step closer to developing a drug to kill the trypanosome parasite that causes human African trypanosomiasis, otherwise known as sleeping sickness, paving the way for a potential cure.
› Verified 2 days ago
Omar Mallah, OD Optometrist Medicare: Medicare Enrolled Practice Location: 29474 7 Mile Rd, Livonia, MI 48152 Phone: 248-615-2815 | |
Dr. James S Engstrom, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 13700 Middlebelt Rd, Livonia, MI 48150 Phone: 734-427-2944 | |
Marston Optometry, P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 32037 Plymouth Rd, Livonia, MI 48150 Phone: 734-421-5454 Fax: 734-421-6133 | |
Mr. Gerald N Blaize, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 33012 7 Mile Rd, Livonia, MI 48152 Phone: 248-482-2020 Fax: 248-476-6441 | |
Svs Vision 06 Optometrist Medicare: Not Enrolled in Medicare Practice Location: 29691 7 Mile Rd, Livonia, MI 48152 Phone: 734-421-2844 Fax: 734-421-2878 | |
K & K Optical Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 28209 7 Mile Rd, Livonia, MI 48152 Phone: 248-777-2830 Fax: 248-777-9376 | |
Dr. Carol Lynn Marston-foucher, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 32037 Plymouth Rd, Livonia, MI 48150 Phone: 734-421-5454 Fax: 734-421-6133 |